Product Pathways - Growth Factors/Cytokines
Human RANKL/TRANCE/TNFSF11 (hRANKL) #5312
Recombinant human RANKL (hRANKL) Gly63-Asp244 (Accession #NP_143026) was expressed in human 293 cells at Cell Signaling Technology.
Recombinant hRANKL contains no "tags" and the nonglycosylated protein has a calculated MW of 20,484. DTT-reduced and non-reduced protein migrate as 30-35 kDa polypeptides. Lower mobility and heterogeneity in SDS-PAGE are due to glycosylation. The expected amino-terminal GSQHI of recombinant hRANKL was verified by amino acid sequencing.
>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hRANKL. All lots are greater than 98% pure.
The bioactivity of hRANKL was determined by measuring the ability of hRANKL to induce TRAP activity in Raw 264.7 cells. The ED50 of each lot is between 1.5-5 ng/ml.
The purity of recombinant hRANKL was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant hRANKL and staining overnight with Coomassie Blue.
Less than 0.01 ng endotoxin/1 μg hRANKL.
With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg hRANKL. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 5% sucrose.
RANKL, also known as TRANCE or OPGL, is a member of the TNF superfamily of ligands. T cells, mammary epithelial cells, and endothelial cells can produce RANKL (1). RANKL is expressed as a type II transmembrane protein or cleaved into a soluble form by extracellular proteases, such as TACE, ADAM10, and matrix metalloproteases (1). Alternative splicing also results in the production of soluble RANKL (1). RANKL signaling is antagonized by osteoprotegerin, which functions as a soluble decoy receptor (2). RANKL plays key roles in mammary gland development and dendritic cell survival and is required for osteoclast differentiation and survival (3-6). Research studies have shown that RANKL deficiencies in both mice and humans are associated with abnormally increased bone density and defects in lymphoid organogenesis (5,6).
- O'Brien, C.A. (2010) Bone 46, 911-9.
- Lacey, D.L. et al. (1998) Cell 93, 165-76.
- Wong, B.R. et al. (1997) J Exp Med 186, 2075-80.
- Fata, J.E. et al. (2000) Cell 103, 41-50.
- Kong, Y.Y. et al. (1999) Nature 397, 315-23.
- Conklin, J.L. et al. (1991) Gastroenterology 101, 657-63.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.